Epilepsy is the most common paediatric neurological disorder, with an average annual rate of 5–7 new cases per 10,000 children [1]. Treatment of epilepsy involves long-term therapy of antiseizure medication, which expose patients to potentially undesirable metabolic bone health adverse effects such as vitamin D deficiency [2]. Vitamin D is an important determinant of growth and body development during childhood and adolescence [3–5]. Paediatric studies have shown that long-term antiseizure medication therapy is associated with vitamin D deficiency resulting in impaired bone health including reduced bone mineral density (BMD) and osteoporotic fractures in childhood and in later adult life [6–9].
24
MAY
MAY
0